A Novel Immune-Associated Gene Signature for Overall Survival Prediction in Patients with Oral Squamous Cell Carcinoma
Author(s) -
Jian Yang,
Zhien Feng,
Xiaohong Yuan,
Zhengxue Han
Publication year - 2022
Publication title -
evidence-based complementary and alternative medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.552
H-Index - 90
eISSN - 1741-4288
pISSN - 1741-427X
DOI - 10.1155/2022/1063130
Subject(s) - proportional hazards model , oncology , medicine , receiver operating characteristic , basal cell , gene , immune system , gene signature , biology , gene expression , immunology , genetics
Objective. To explore a novel Immune-associated gene signature for overall survival (OS) in patients with oral squamous cell carcinoma (OSCC). Methods. Expression profiles of genes and corresponding clinical materials of OSCC patients were obtained through the TCGA database. With a LASSO Cox regression model, a multigene signature was established to predict the OS of OSCC patients. Some molecular experiments including RNA interference, MTT, and Transwell assay were applied to verify the role of the risk gene FGF9 in OSCC. Results. 43 immune-related prognostic DEGs were identified in OSCC. A 17-gene signature was established to assign the patients to either a high-risk group (HG) or a low-risk group (LG). The HG presented a shorter OS than the LG ( P < 0.05 ). According to multivariate Cox regression analyses, the risk score was considered an independent factor for OS prediction (training set: HR = 3.485, 95% CI = 2.037–5.961, P < 0.001 ; test set: HR = 4.531, 95% CI = 2.120–9.682, P < 0.001 ). ROC curve-based analysis revealed the signature’s ability for prediction. According to functional analysis, the immune cell expression and immune function of the HG were significantly inhibited. After knocking down the high-risk gene FGF9, the migration, proliferation, and invasion capabilities of OSCC cells HSC6 were significantly suppressed ( P < 0.05 ). Conclusion. A novel immune-associated gene signature was identified for predicting the prognosis of OSCC. These risk genes show great potential as targets for OSCC treatment.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom